drugset / Trial / NCT02499081
UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effect of Ixazomib on inducing osteoblast activation as measured by bone markers and imaging in patients with relapsed/refractory myeloma.
Timeline
- Start
- 2015-09
- Primary completion
- 2018-05-17
- Completion
- 2018-05-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixazomib | Unknown | 4 mg | — |